Foundayo vs Wegovy Pill: How the Two Oral GLP-1s Compare

Foundayo (orforglipron) and the Wegovy pill (oral semaglutide 25 mg) are two once-daily oral GLP-1 weight-loss tablets sold in the United States, and they differ most in how you take them, what they are approved to treat, and what they cost. Foundayo is a small-molecule GLP-1 receptor agonist that can be taken any time of day with or without food ^[1][3]. The Wegovy pill is a tablet form of semaglutide that must be taken on an empty stomach in the morning, with a 30-minute wait before eating or drinking anything else ^[2]. No randomized trial has pitted these two weight-loss pills against each other. The only head-to-head Phase 3 trial of two oral GLP-1 receptor agonists, ACHIEVE-3, compared orforglipron against oral semaglutide at diabetes doses in people with type 2 diabetes — not Foundayo against the Wegovy 25 mg weight pill ^[4][2].

Both drugs carry a boxed warning about the risk of thyroid C-cell tumors, but the label language differs. The Wegovy label states that semaglutide causes thyroid C-cell tumors in rodents at clinically relevant exposures and that human relevance has not been determined ^[2]. The Foundayo label states that orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents, and that the human relevance of GLP-1 receptor-dependent rodent thyroid C-cell tumors has not been determined ^[1]. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 ^[1][2]. Neither pill should be combined with another GLP-1 receptor agonist ^[1][2].

What exactly are Foundayo and the Wegovy pill?

Foundayo is the brand name for orforglipron tablets, a GLP-1 receptor agonist with an Initial U.S. Approval of 2026 ^[1]. Orforglipron is a once-daily small molecule — meaning it is not a peptide — that was discovered by Chugai Pharmaceutical and licensed by Lilly in 2018 ^[3][4].

The Wegovy pill is a tablet version of semaglutide, a peptide GLP-1 receptor agonist. Wegovy’s Initial U.S. Approval was 2017, and the product is now marketed both as an injection and as tablets in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths ^[2]. The weight-management pill became available in the US on January 5, 2026 ^[7].

Orforglipron is marketed as a pill that can be taken any time of day without restrictions on food and water intake ^[3][4]. Semaglutide tablets, by contrast, come with strict fasting instructions described below ^[2].

What is each pill approved to treat?

This is where the two products diverge most. Foundayo is approved, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain that reduction long term in adults with obesity, or adults with overweight who have at least one weight-related comorbid condition ^[1]. Its label states that concomitant use with another GLP-1 receptor agonist is not recommended ^[1].

Wegovy tablets carry that same weight-loss indication for adults with obesity or overweight plus weight-related medical problems ^[7], but they also carry an indication the Foundayo label does not have: reducing the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, or non-fatal stroke — in adults with established cardiovascular disease who also have obesity or overweight ^[2].

The Wegovy injection has additional approved uses the tablets do not: weight management in patients aged 12 and older with obesity, and treatment of noncirrhotic MASH with F2 to F3 fibrosis under accelerated approval ^[2].

Foundayo has no approved US diabetes indication. As of February 26, 2026, Lilly said its US type 2 diabetes submission was planned for later that year ^[4].

How do the daily dosing rules differ?

This is the day-to-day difference most people notice first.

Foundayo is taken orally once daily, with or without food, at any time of day. Tablets are swallowed whole — not broken, crushed, or chewed — and no more than one tablet is taken per day ^[1]. Lilly markets orforglipron as taken any time of day without restrictions on food and water intake ^[3][4].

Wegovy tablets are taken once daily on an empty stomach in the morning, with water only, up to 4 ounces, and no other liquids. The tablet is swallowed whole and must not be split, crushed, chewed, or dissolved. After taking it, you wait at least 30 minutes before any food, drink, or other oral medications ^[2].

Both drugs delay gastric emptying and can affect how other oral medications are absorbed ^[1][2].

How long does it take to reach the top dose of each?

Both pills use a stepwise titration, and both move in roughly 30-day steps, but the ladders are different.

Foundayo tablets come in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg strengths ^[1]. The label says to start at 0.8 mg once daily, increase to 2.5 mg after at least 30 days, then to 5.5 mg after at least another 30 days. Further increases to 9 mg, 14.5 mg, or 17.2 mg can happen at 30-day intervals based on response and tolerability, with 17.2 mg once daily as the maximum dosage ^[1].

Wegovy tablets come in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths ^[2]. The label says to start at 1.5 mg once daily for 30 days, then follow the escalation schedule, titrating every 30 days to reach the maintenance dosage ^[2]. The weight-management pill is marketed as semaglutide tablets 25 mg ^[7].

All dosing decisions are label information to discuss with a prescriber — the titration schedule is not a suggestion to adjust a dose on your own.

How much weight did people lose on Foundayo in its Phase 3 trial?

Foundayo’s pivotal weight data come from ATTAIN-1, a Phase 3, 72-week trial that randomized 3,127 adults with obesity or overweight plus at least one comorbidity, without diabetes ^[3]. Participants had an average starting weight of 103.2 kg (227.5 lbs) and BMI of 37.0 ^[3].

An important note on doses: ATTAIN-1 studied investigational doses of 6 mg, 12 mg, and 36 mg ^[3]. These are trial doses, not the marketed Foundayo tablet strengths of 0.8 mg through 17.2 mg, and the trial results are reported at those trial doses rather than at the marketed strengths ^[3][1].

At the highest trial dose, participants lost an average of 12.4% of body weight (27.3 lbs) at week 72 on the efficacy estimand, versus 0.9% (2.2 lbs) with placebo ^[3]. On the treatment-regimen estimand, the highest dose showed 11.2% (25.0 lbs) versus 2.1% (5.3 lbs) for placebo ^[3]. Lower trial arms lost 7.8% (17.6 lbs) at 6 mg and 9.3% (20.7 lbs) at 12 mg on the efficacy estimand ^[3].

ATTAIN-1 result at week 72 (efficacy estimand)	Orforglipron 36 mg	Placebo
Mean weight change	-12.4% (-27.3 lbs)	-0.9% (-2.2 lbs)
Lost ≥10% of body weight	59.6%	8.6%
Lost ≥15% of body weight	39.6%	3.6%
Lost ≥20% of body weight	20.1%	1.6%
Waist circumference	-11.1 cm (-4.4 in)	-2.1 cm

Other findings at the highest dose included a 47.7% reduction in hsCRP, a 6.7 mm Hg drop in systolic blood pressure, a 21.6% drop in triglycerides, and an 8.5% drop in non-HDL cholesterol ^[3]. Among the 1,127 participants who started the trial with prediabetes, up to 91% on orforglipron reached near-normal blood sugar versus 42% on placebo ^[3]. ATTAIN-1 was also the first Phase 3 trial in this population to test treatment as an adjunct to exercise and a balanced healthy diet rather than a reduced-calorie diet ^[3]. Results were published in the New England Journal of Medicine and presented at EASD 2025, announced September 16, 2025 ^[3].

Is there any head-to-head trial between the two pills?

Not for weight loss. The only randomized head-to-head comparison of two oral GLP-1 receptor agonists is ACHIEVE-3, and it was run in type 2 diabetes, not weight management ^[4].

ACHIEVE-3 was a Phase 3, 52-week, open-label trial that randomized 1,698 adults with type 2 diabetes inadequately controlled on metformin in a 1:1:1:1 ratio to orforglipron 12 mg, orforglipron 36 mg, oral semaglutide 7 mg, or oral semaglutide 14 mg ^[4]. The comparator doses were the oral semaglutide diabetes doses — not the 25 mg weight-management tablet ^[4][2].

Starting from an average A1C of 8.3%, the efficacy estimand showed A1C reductions of 1.1% with semaglutide 7 mg, 1.4% with semaglutide 14 mg, 1.9% with orforglipron 12 mg, and 2.2% with orforglipron 36 mg ^[4]. Weight loss from a baseline of 97.0 kg (213.9 lbs) was 3.7% (-7.9 lbs) with semaglutide 7 mg, 5.3% (-11.0 lbs) with semaglutide 14 mg, 6.7% (-14.6 lbs) with orforglipron 12 mg, and 9.2% (-19.7 lbs) with orforglipron 36 mg ^[4]. Lilly framed the top-dose comparison as 73.6% greater relative weight loss for orforglipron 36 mg versus oral semaglutide 14 mg ^[4].

ACHIEVE-3 at week 52 (efficacy estimand)	Oral semaglutide 7 mg	Oral semaglutide 14 mg	Orforglipron 12 mg	Orforglipron 36 mg
A1C change from 8.3%	-1.1%	-1.4%	-1.9%	-2.2%
Weight change from 97.0 kg	-3.7% (-7.9 lbs)	-5.3% (-11.0 lbs)	-6.7% (-14.6 lbs)	-9.2% (-19.7 lbs)
Reached A1C <7%	54.6%	66.1%	80.0%	85.4%
Reached A1C <5.7%	7.8%	12.5%	25.4%	37.1%
Quit due to adverse events	4.5%	4.9%	8.7%	9.7%

The trial was published in The Lancet and announced February 26, 2026 ^[4]. Because it tested diabetes doses of oral semaglutide in a diabetes population, it does not settle which pill produces more weight loss in people taking them for weight management.

On September 29, 2026, Lilly reported an indirect treatment comparison of Foundayo 17.2 mg and oral semaglutide 25 mg — the strength marketed as the Wegovy pill — in adults with type 2 diabetes at 52 weeks ^[14][2]. It found 1.5% greater weight loss for Foundayo (95% CI -2.7% to -0.2%) and 0.3% greater A1C reduction (95% CI -0.6% to -0.1%); across different statistical methods the results ranged from 1.5% to 2.4% greater weight loss and 0.3% to 0.6% greater A1C reduction, and the analysis was covariate-adjusted for gender, age, baseline A1C, and baseline weight ^[14].

How do the side effects and warnings compare?

The two labels overlap heavily because both drugs are GLP-1 receptor agonists. Both carry a boxed warning about the risk of thyroid C-cell tumors, and both are contraindicated with a personal or family history of MTC or MEN 2, and with known serious hypersensitivity to the drug or its ingredients ^[1][2]. One nuance in the Foundayo label: orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents, so the human relevance of GLP-1 receptor-dependent rodent tumors is undetermined ^[1].

The most common reactions listed for Foundayo (reported in at least 5% of patients) are nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, GERD, flatulence, and hair loss ^[1]. The Wegovy list is similar: nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, GERD, and hair loss ^[2].

In ATTAIN-1, the most common adverse events by trial dose (6 mg, 12 mg, 36 mg versus placebo) were nausea at 28.9%, 35.9%, and 33.7% versus 10.4%; constipation at 21.7%, 29.8%, and 25.4% versus 9.3%; diarrhea at 21.0%, 22.8%, and 23.1% versus 9.6%; and vomiting at 13.0%, 21.4%, and 24.0% versus 3.5% ^[3]. Discontinuation due to adverse events was 5.3%, 7.9%, and 10.3% versus 2.7% on placebo, and no hepatic safety signal was observed ^[3].

In ACHIEVE-3, discontinuation due to adverse events was roughly twice as high on orforglipron — 8.7% at 12 mg and 9.7% at 36 mg — as on oral semaglutide, at 4.5% (7 mg) and 4.9% (14 mg) ^[4].

Shared warnings on both labels include acute pancreatitis, severe gastrointestinal reactions, acute kidney injury from volume depletion, hypoglycemia when combined with insulin or insulin secretagogues, hypersensitivity, diabetic retinopathy complications, gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation ^[1][2]. Wegovy adds a warning on heart rate increase with monitoring at regular intervals, and a warning to never share the FlexTouch pen ^[2].

Foundayo has drug-interaction rules the Wegovy label does not show: a maximum of 9 mg once daily when used with a strong CYP3A4 inhibitor, avoiding strong CYP3A4 inhibitors that also inhibit OATP1B, avoiding strong CYP3A4 inducers, and not exceeding simvastatin 20 mg daily when taken together ^[1]. Foundayo is not recommended in severe hepatic impairment or severe gastroparesis ^[1].

Both labels address pregnancy: both drugs may cause fetal harm, and the Wegovy label says to discontinue at least 2 months before a planned pregnancy because of semaglutide’s long half-life ^[1][2]. The Foundayo label also advises females using oral contraceptives to switch to a non-oral method or add a barrier method for 30 days after starting treatment and for 30 days after each dose escalation ^[1]. The Foundayo label was revised 7/2026 and the Wegovy label 06/2026 ^[1][2].

Which pill is being prescribed more?

The Wegovy pill has a large early lead. It surpassed 3 million US prescriptions in just over five months after its January 5, 2026 launch, a milestone Novo Nordisk announced on June 7, 2026 ^[7]. It hit its first million prescriptions 12 weeks after launch and the next two million in only 10 weeks ^[7]. Novo Nordisk said more than 80% of new Wegovy pill prescriptions are for people new to GLP-1 therapy, based on an 82% new-to-brand figure from IQVIA LRx data year-to-date 2026 ^[7].

Weekly prescription counts show the gap. In the week reported September 4, 2026, IQVIA data cited by Citi showed the Wegovy pill at roughly 181,000 total prescriptions (+3%) and Foundayo at roughly 44,000 (+8%) — both records at the time ^[6]. The following week, reported September 11, 2026, the Wegovy pill reached about 183,000 and Foundayo climbed nearly 8% to 47,500 ^[6]. Foundayo’s weekly totals have progressed from 24,303 to 26,760, 29,388, 34,219, 38,928, 36,620, and 40,862 across recent weeks ^[6].

Weekly total prescriptions (IQVIA, cited by Citi)	Wegovy pill	Foundayo
Week reported Sept. 4, 2026	~181K (+3%)	~44K (+8%)
Week reported Sept. 11, 2026	~183K	47.5K (+~8%)

These are prescription counts, not sales, and Citi cautioned that IQVIA may miss Foundayo prescriptions filled through telehealth channels ^[6]. A Jefferies note dated August 28, 2026 put Foundayo’s share of new prescriptions in the oral obesity market at 21.5% ^[6].

Other market context from the same tracker: the Wegovy pill accounts for about 35% of all Wegovy prescriptions, with total Wegovy scripts at 513,500 in the September 4 reporting week and Lilly’s Zepbound just under 772,000 ^[6]. Lilly reported $98 million in total Foundayo sales for the second quarter of 2026, including $67 million in the US, after securing commercial access across three major PBMs in June and beginning broad direct-to-consumer marketing ^[6]. Total GLP-1 prescriptions rose 5.4% over the trailing four weeks versus a 6.8% decline a year earlier — a 12-point swing Citi attributed to the expansion of oral GLP-1s ^[6]. Across the total GLP-1 market, Lilly’s tirzepatide holds about 57% share versus roughly 49.5% a year earlier, while Novo’s semaglutide sits at about 37% ^[6].

What do they cost, and how does coverage work?

Both manufacturers offer savings-card pricing for commercially insured patients, and both exclude government beneficiaries. These card prices are not cash prices — they require commercial insurance coverage and carry caps and exclusions.

With commercial drug insurance, Foundayo starts at as little as $25 per month with the Foundayo Savings Card; savings are subject to monthly and annual limits, a month is defined as 30 days, and the program is not insurance ^[9]. Wegovy with commercial insurance is available for as little as $25 per month through existing savings programs, subject to a maximum savings of $100 per month, with government beneficiaries excluded and a month defined as one bottle of 30 tablets or one box of 4 pens ^[7].

For people paying cash, the Lilly coverage page lists Foundayo self-pay pricing starting at $149 per month for the 0.8 mg and 2.5 mg dosages, with the 2.5 mg price temporarily reduced through December 31, 2026 ^[9].

For Medicare Part D patients, the Medicare GLP-1 Bridge program offers a $50 monthly copay. It covers Foundayo for weight management for eligible Part D patients, with eligibility based on clinical criteria set by CMS ^[9]. It also covers Wegovy injection and tablets at a $50 monthly copay beginning July 1, 2026, with CMS determining eligibility ^[7]. The Bridge program went live July 1, 2026 ^[6].

Cost channel	Foundayo	Wegovy
Commercial insurance + savings card	As little as $25/month [9]	As little as $25/month (max savings $100/month) [7]
Self-pay	Starting at $149/month (0.8 and 2.5 mg) [9]	Not listed in the materials cited [7]
Medicare GLP-1 Bridge	$50/month copay [9]	$50/month copay [7]

Wegovy is available through more than 70,000 US pharmacies, NovoCare Pharmacy, and select telehealth providers ^[7]. Foundayo can be purchased through LillyDirect or another pharmacy, and savings or self-pay payments may be HSA or FSA eligible depending on the plan ^[9].

What factors matter when choosing between them?

Several practical differences are worth raising with a prescriber:

• Daily routine. Foundayo has no food, water, or timing restrictions ^[1][3], while the Wegovy pill requires a fasted morning dose with water only and a 30-minute wait before food, drink, or other oral medications ^[2].
• Heart disease. Only Wegovy tablets carry an indication to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight ^[2]. Foundayo has no cardiovascular risk-reduction indication ^[1].
• Type 2 diabetes. ACHIEVE-3 favored orforglipron on both A1C and weight, but with roughly double the adverse-event discontinuation rate of oral semaglutide ^[4]. Foundayo has no approved US diabetes indication ^[4].
• Other medications. Foundayo’s limits around strong CYP3A4 inhibitors and inducers, and its simvastatin 20 mg cap, make it a conversation for anyone taking multiple drugs — a pharmacist can help review this ^[1].
• Birth control. People using oral contraceptives need backup contraception windows when starting Foundayo and after each dose escalation ^[1].
• Cost and coverage. Both offer $25-per-month card pricing with commercial insurance and $50-per-month Medicare Bridge copays, but self-pay details differ ^[7][9].

Whether to start one pill or the other, switch, or stay on a current treatment is a decision for a prescriber who knows your full history — the information above is label and trial data to bring to that conversation.

Sources

1. Eli Lilly and Company. FOUNDAYO (orforglipron) tablets, for oral use. Prescribing information. Initial U.S. approval 2026.
2. Novo Nordisk. Wegovy prescribing information.
3. Eli Lilly and Company. Lilly’s oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine. September 16, 2025.
4. Eli Lilly and Company. Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet. February 26, 2026.
5. The Lancet. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
6. Fierce Pharma. The Oral GLP-1 Tracker: Novo’s Wegovy pill, Lilly’s Foundayo continue prescription climb. September 11, 2026.
7. Novo Nordisk. Wegovy pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated. June 7, 2026.
8. Reddit. r/NovoNordisk_Stock discussion post about Wegovy pill weight loss results.
9. Eli Lilly and Company. Foundayo (orforglipron) coverage and savings: self-pay and savings card.
10. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge.
11. BioPharma Dive. How cost and perception could reshape the GLP-1 market.
12. PR Newswire. Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress.
13. Eli Lilly and Company. Foundayo cost information: with or without insurance.
14. BioSpace. Lilly’s Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison.
15. PubMed. Checking your browser - reCAPTCHA.